| Dr Ryan Richard Sturm, DO | |
|
1 Genesys Pkwy, Grand Blanc, MI 48439-8065 | |
| (319) 415-4560 | |
| Not Available |
| Full Name | Dr Ryan Richard Sturm |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1 Genesys Pkwy, Grand Blanc, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548589245 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 5101018645 (Michigan) | Primary |
| 207P00000X | Emergency Medicine | 2014002142 (Missouri) | Secondary |
| Entity Name | Northwest Medical Center Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124164322 PECOS PAC ID: 5496641896 Enrollment ID: O20040224000204 |
News Archive
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
A comprehensive study of oral oncolytic (anti-cancer) drug treatments revealed that while their use is increasingly common, cancer patients frequently face barriers to accessing oral drugs compared to those delivered intravenously in oncology practice settings.
AccessClosure Inc., the market leader in extravascular care technology, has commercially launched its Mynx Ace Vascular Closure Device, a safe and secure vascular closure product that provides consistent results with a new, easy-to-use deployment system to seal femoral artery access sites.
Sphere Fluidics, introduced the Cyto-Cellect Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System.
Staphylococcus aureus is a common colonizer of the human body. Although, one quarter of the U.S. population live with the bacteria and never get sick, having S. aureus present in the nostrils is a risk for infections that range in severity from mild skin to life- threatening MRSA infections.
› Verified 6 days ago
| Entity Name | Heartland Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477575405 PECOS PAC ID: 6709772767 Enrollment ID: O20040225001201 |
News Archive
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
A comprehensive study of oral oncolytic (anti-cancer) drug treatments revealed that while their use is increasingly common, cancer patients frequently face barriers to accessing oral drugs compared to those delivered intravenously in oncology practice settings.
AccessClosure Inc., the market leader in extravascular care technology, has commercially launched its Mynx Ace Vascular Closure Device, a safe and secure vascular closure product that provides consistent results with a new, easy-to-use deployment system to seal femoral artery access sites.
Sphere Fluidics, introduced the Cyto-Cellect Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System.
Staphylococcus aureus is a common colonizer of the human body. Although, one quarter of the U.S. population live with the bacteria and never get sick, having S. aureus present in the nostrils is a risk for infections that range in severity from mild skin to life- threatening MRSA infections.
› Verified 6 days ago
| Entity Name | Mosaic Medical Center - Maryville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184189797 PECOS PAC ID: 3678813896 Enrollment ID: O20190405001537 |
News Archive
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
A comprehensive study of oral oncolytic (anti-cancer) drug treatments revealed that while their use is increasingly common, cancer patients frequently face barriers to accessing oral drugs compared to those delivered intravenously in oncology practice settings.
AccessClosure Inc., the market leader in extravascular care technology, has commercially launched its Mynx Ace Vascular Closure Device, a safe and secure vascular closure product that provides consistent results with a new, easy-to-use deployment system to seal femoral artery access sites.
Sphere Fluidics, introduced the Cyto-Cellect Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System.
Staphylococcus aureus is a common colonizer of the human body. Although, one quarter of the U.S. population live with the bacteria and never get sick, having S. aureus present in the nostrils is a risk for infections that range in severity from mild skin to life- threatening MRSA infections.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ryan Richard Sturm, DO 5301 Faraon St Ste 120, Saint Joseph, MO 64506-3512 Ph: (816) 271-1066 | Dr Ryan Richard Sturm, DO 1 Genesys Pkwy, Grand Blanc, MI 48439-8065 Ph: (319) 415-4560 |
News Archive
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.
A comprehensive study of oral oncolytic (anti-cancer) drug treatments revealed that while their use is increasingly common, cancer patients frequently face barriers to accessing oral drugs compared to those delivered intravenously in oncology practice settings.
AccessClosure Inc., the market leader in extravascular care technology, has commercially launched its Mynx Ace Vascular Closure Device, a safe and secure vascular closure product that provides consistent results with a new, easy-to-use deployment system to seal femoral artery access sites.
Sphere Fluidics, introduced the Cyto-Cellect Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System.
Staphylococcus aureus is a common colonizer of the human body. Although, one quarter of the U.S. population live with the bacteria and never get sick, having S. aureus present in the nostrils is a risk for infections that range in severity from mild skin to life- threatening MRSA infections.
› Verified 6 days ago
Dr. Tara Knisely, MD, MPH Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-5000 | |
Alison Marie Ralston, Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-6372 | |
Brian T West, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-6137 | |
Dr. Brendan Haigis, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-6372 | |
Roland R Tindle, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 8401 Holly Rd, Grand Blanc, MI 48439 Phone: 810-695-8011 Fax: 810-695-8002 | |
Dr. Ryan Patrick Kirby, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Genesys Pkwy, Grand Blanc, MI 48439 Phone: 810-606-5000 | |
Dr. John Nicholas Vitali, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Genesys Parkway, Grand Blanc, MI 48439 Phone: 810-606-5000 |